Arcadia Biosciences Inc (NASDAQ:RKDA) saw a large increase in short interest in the month of August. As of August 31st, there was short interest totalling 1,697,500 shares, an increase of 1,790.3% from the July 31st total of 89,800 shares. Based on an average daily trading volume, of 2,750,000 shares, the short-interest ratio is currently 0.6 days. Currently, 36.3% of the company’s shares are sold short.

Shares of NASDAQ:RKDA traded down $0.04 during trading hours on Wednesday, hitting $6.30. The company’s stock had a trading volume of 1,244,552 shares, compared to its average volume of 1,479,352. The firm’s fifty day moving average price is $5.29 and its 200 day moving average price is $5.36. Arcadia Biosciences has a 52 week low of $1.82 and a 52 week high of $10.40. The company has a market capitalization of $40.11 million, a price-to-earnings ratio of -1.18 and a beta of -2.94. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.29 and a quick ratio of 5.09.

In other news, CFO Matthew T. Plavan bought 8,000 shares of the firm’s stock in a transaction on Wednesday, August 28th. The stock was acquired at an average cost of $8.73 per share, with a total value of $69,840.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Kevin Comcowich bought 15,000 shares of the firm’s stock in a transaction on Tuesday, September 10th. The shares were purchased at an average cost of $6.49 per share, with a total value of $97,350.00. Following the completion of the transaction, the director now owns 5,000 shares in the company, valued at $32,450. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 26,200 shares of company stock valued at $187,986. 3.30% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RKDA. Vanguard Group Inc. boosted its stake in shares of Arcadia Biosciences by 47.1% during the second quarter. Vanguard Group Inc. now owns 117,059 shares of the basic materials company’s stock valued at $359,000 after purchasing an additional 37,472 shares in the last quarter. Morgan Stanley raised its stake in Arcadia Biosciences by 162,800.0% in the second quarter. Morgan Stanley now owns 81,450 shares of the basic materials company’s stock worth $250,000 after buying an additional 81,400 shares in the last quarter. Citadel Advisors LLC bought a new position in Arcadia Biosciences in the second quarter worth approximately $32,000. Cambridge Investment Research Advisors Inc. bought a new position in Arcadia Biosciences in the second quarter worth approximately $34,000. Finally, CVI Holdings LLC purchased a new stake in Arcadia Biosciences during the second quarter worth $414,000. Hedge funds and other institutional investors own 7.67% of the company’s stock.

A number of equities analysts have recently issued reports on RKDA shares. National Securities increased their price target on Arcadia Biosciences from $12.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th. ValuEngine downgraded Arcadia Biosciences from a “hold” rating to a “sell” rating in a report on Thursday, August 15th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Arcadia Biosciences in a research note on Monday, August 12th.

About Arcadia Biosciences

Arcadia Biosciences, Inc, an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits.

Recommended Story: Cost of Equity

Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.